Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Life Sciences	$1.46 -4.6%	$1.49	$1.03 ▼ $2.57	$291.68M	1.24	1.50 million shs	2.23 million shs
AURA Aura Biosciences	$5.38 -2.5%	$6.52	$4.84 ▼ $12.38	$270.21M	0.43	201,935 shs	244,554 shs
PVLA Palvella Therapeutics	$25.39 -0.3%	$24.02	$6.20 ▼ $29.27	$279.77M	0.1	69,782 shs	65,991 shs
VXRT Vaxart	$0.40 +11.3%	$0.45	$0.29 ▼ $1.07	$91.44M	1.57	2.39 million shs	2.08 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Life Sciences	+0.66%	+4.08%	-2.55%	-3.16%	-18.18%
AURA Aura Biosciences	-4.17%	+2.99%	-22.03%	-30.04%	-22.25%
PVLA Palvella Therapeutics	-4.10%	+4.56%	-6.60%	+103.92%	+2,546,999,900.00%
VXRT Vaxart	+4.74%	+4.68%	-25.17%	-54.14%	-49.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	2.5526 of 5 stars	3.5	1.0	1.8	3.3	1.3
AURA Aura Biosciences	2.3233 of 5 stars	3.6	2.0	2.9	2.5	0.0
PVLA Palvella Therapeutics	3.4935 of 5 stars	4.6	0.0	3.2	2.5	0.6
VXRT Vaxart	1.519 of 5 stars	3.5	1.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Life Sciences	3.00	Buy	$10.50	619.18% Upside
AURA Aura Biosciences	3.25	Buy	$22.75	322.86% Upside
PVLA Palvella Therapeutics	3.13	Buy	$44.43	74.98% Upside
VXRT Vaxart	3.00	Buy	$3.00	648.69% Upside

Current Analyst Ratings Breakdown

Latest VXRT, ATAI, PVLA, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
4/1/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
3/27/2025	VXRT Vaxart	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.50 ➝ $2.00
3/26/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$19.00
3/26/2025	AURA Aura Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/26/2025	PVLA Palvella Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$45.00
3/25/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$25.00
3/25/2025	PVLA Palvella Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$45.00
3/24/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/24/2025	PVLA Palvella Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/19/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Life Sciences	$308K	947.00	N/A	N/A	$1.47 per share	0.99
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$4.58 per share	N/A
PVLA Palvella Therapeutics	$42.81M	6.54	N/A	N/A	$21.66 per share	1.17
VXRT Vaxart	$28.70M	3.19	N/A	N/A	$0.38 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Life Sciences	-$40.22M	-$0.93	N/A	N/A	N/A	N/A	-65.75%	-52.71%	5/13/2025 (Estimated)
AURA Aura Biosciences	-$76.41M	-$1.75	N/A	N/A	N/A	N/A	-41.57%	-36.43%	5/8/2025 (Estimated)
PVLA Palvella Therapeutics	-$24.54M	-$12.10	N/A	N/A	N/A	N/A	-80.93%	-59.55%	5/13/2025 (Estimated)
VXRT Vaxart	-$82.46M	-$0.34	N/A	N/A	N/A	-431.61%	-110.46%	-62.78%	5/12/2025 (Estimated)

Latest VXRT, ATAI, PVLA, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	N/A	N/A	N/A	N/A	N/A
5/21/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	VXRT Vaxart	-$0.07	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	AURA Aura Biosciences	-$0.45	N/A	N/A	N/A	N/A	N/A
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A
3/20/2025	Q4 2024	VXRT Vaxart	-$0.10	-$0.05	+$0.05	-$0.05	$15.68 million	$15.19 million
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
AURA Aura Biosciences	N/A	12.47	12.47
PVLA Palvella Therapeutics	N/A	4.82	4.82
VXRT Vaxart	N/A	0.83	0.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Life Sciences	28.41%
AURA Aura Biosciences	96.75%
PVLA Palvella Therapeutics	40.11%
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
ATAI Atai Life Sciences	31.20%
AURA Aura Biosciences	5.40%
PVLA Palvella Therapeutics	6.39%
VXRT Vaxart	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Life Sciences	80	199.78 million	115.45 million	Optionable
AURA Aura Biosciences	50	50.23 million	47.25 million	Not Optionable
PVLA Palvella Therapeutics	N/A	11.02 million	10.50 million	N/A
VXRT Vaxart	120	228.21 million	221.57 million	Optionable

VXRT, ATAI, PVLA, and AURA Headlines

Recent News About These Companies

Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?

April 24 at 5:00 AM | marketbeat.com

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

April 16, 2025 | globenewswire.com

Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average - Here's What Happened

April 10, 2025 | marketbeat.com

B. Riley Issues Positive Outlook for Vaxart Earnings

March 31, 2025 | marketbeat.com

Vaxart (NASDAQ:VXRT) Price Target Lowered to $2.00 at B. Riley

March 28, 2025 | marketbeat.com

Vaxart price target lowered to $2 from $2.50 at B. Riley

March 27, 2025 | markets.businessinsider.com

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 27, 2025 | globenewswire.com

Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript

March 24, 2025 | insidermonkey.com

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

March 20, 2025 | seekingalpha.com

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

March 20, 2025 | zacks.com

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

March 20, 2025 | globenewswire.com

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

March 14, 2025 | markets.businessinsider.com

Vaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025

March 13, 2025 | quiverquant.com

Vaxart announces trial initiation of norovirus oral pill vaccine candidate

March 11, 2025 | markets.businessinsider.com

Vaxart, Inc. Launches Phase 1 Clinical Trial for Second-Generation Oral Norovirus Vaccine Constructs

March 11, 2025 | quiverquant.com

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

March 11, 2025 | globenewswire.com

Vaxart announces norovirus vaccine candidate trial data published

March 5, 2025 | markets.businessinsider.com

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

March 5, 2025 | globenewswire.com

Multimillion-dollar Biden-era COVID-19 vax project halted by Trump’s HHS

February 26, 2025 | msn.com

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

January 28, 2025 | markets.businessinsider.com

Vaxart appoints Kevin Finney to board of directors

January 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VXRT, ATAI, PVLA, and AURA Company Descriptions

Atai Life Sciences NASDAQ:ATAI

$1.46 -0.07 (-4.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 +0.00 (+0.27%)

As of 07:43 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Aura Biosciences NASDAQ:AURA

$5.38 -0.14 (-2.54%)

Closing price 04:00 PM Eastern

Extended Trading

$5.38 0.00 (0.00%)

As of 04:27 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Palvella Therapeutics NASDAQ:PVLA

$25.39 -0.08 (-0.31%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Vaxart NASDAQ:VXRT

$0.40 +0.04 (+11.31%)

Closing price 04:00 PM Eastern

Extended Trading

$0.40 +0.00 (+0.82%)

As of 07:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time